[Pubmed] Infections and hypogammaglobulinemia in myasthenia gravis patients receiving low-dose rituximab: a real-world c
Posté : 12 sept. 2026 12:00
Front Immunol. 2026 Aug 28;17:1907574. doi: 10.3389/fimmu.2026.1907574. eCollection 2026.
ABSTRACT
AIMS: We investigated the incidence of infections and hypogammaglobulinemia (HGG) in patients with myasthenia gravis (MG) receiving long-term low-dose rituximab (RTX) maintenance therapy and identified related risk factors.
METHODS: This single-center retrospective cohort study enrolled MG patients treated with low-dose RTX maintenance. Cox proportional hazards regression was performed to analyze risk factors for infections and HGG.
RESULTS: A total of 186 patients were included. The median age at RTX initiation was 52.50 years, and the median follow-up was 2.41 years. Infections occurred in 29 patients (15.59%), with a median time to first infection of 170.37 days, mostly during the first cycle. The 1- and 2-year infection rates were 13.41 (95% confidence interval [CI], 8.47-20.28) and 9.20 (95% CI, 6.06-13.36) per 100 person-years. Severe infections developed in 21 patients (11.29%). The most prevalent infection was lower respiratory tract infection (LRTI), with 19 episodes (61.29%). HGG was present in 51 patients (27.42%). HGG was an independent risk factor for infection (HR = 5.53, P
Source: https://pubmed.ncbi.nlm.nih.gov/4272921 ... 7&v=2.20.1